• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Retracted Synergistic effects of co ‑expression plasmid‑based ADAM10‑specific siRNA and GRIM‑19 on hepatocellular carcinoma < em > in  vitro < /em > and < em > in  vivo < /em >
Oncol Rep. 2022 Feb;47(2):24. doi: 10.3892/or.2021.8235. Epub 2021 Nov 29.ABSTRACTFollowing the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that various data featured in several of the figures were strikingly similar to data appearing in different form in other articles by different authors. An independent enquiry was launched by the Editorial Office, which revealed that cell migration assay data featured in Fig. 5A and C of the above article had been included in another article written by different authors submitted for publication some 12 months previously. Owing to the fa...
Source: Oncology Reports - November 29, 2021 Category: Cancer & Oncology Authors: Songyang Liu Wei Zhang Kai Liu Yingchao Wang Bai Ji Yahui Liu Source Type: research

Corrigendum MicroRNA ‑122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma
Oncol Rep. 2021 Jul;46(1):122. doi: 10.3892/or.2021.8073. Epub 2021 May 13.ABSTRACTFollowing the publication of the above article, an interested reader drew to the authors' attention that Figs. 6C and 7A apparently contained overlapping panels, suggesting that these data for purportedly different experiments had been derived from the same original source. The wound‑healing result for the anti‑miR‑122+siRNA PKM2 experiment in the lower panel of Fig. 6C and the transwell invasion result for the anti‑miR‑122+siRNA PKM2 experiment in Fig. 7A were erroneously selected. Accordingly, the authors repeated these assays an...
Source: Oncology Reports - May 13, 2021 Category: Cancer & Oncology Authors: Qiuran Xu Meiqi Zhang Jianfeng Tu Linxiao Pang Wenwei Cai Xin Liu Source Type: research

Long non ‑coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR‑675.
In conclusion, our study provides new clues for further clinical treatment of sorafenib‑resistant liver cancer patients. PMID: 32627034 [PubMed - as supplied by publisher]
Source: Oncology Reports - July 7, 2020 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Upregulation of thyroid hormone receptor interactor  13 is associated with human hepatocellular carcinoma.
Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma. Oncol Rep. 2018 Oct 04;: Authors: Ju L, Li X, Shao J, Lu R, Wang Y, Bian Z Abstract Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide. Thyroid hormone receptor interactor 13 (TRIP13) has been reported to promote nonhomologous end joining (NHEJ). However, the role of TRIP13 in the molecular pathogenesis of HCC remains to be elucidated. The aim of the present study was to investigate the role and potential mechanism of TRIP13 in HCC. Real-time PCR a...
Source: Oncology Reports - December 15, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

MicroRNA ‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7.
MicroRNA‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7. Oncol Rep. 2018 Dec 06;: Authors: Tang X, Yang W, Shu Z, Shen X, Zhang W, Cen C, Cao L, Zhang M, Zheng S, Yu J Abstract Hepatocellular carcinoma (HCC) is a globally prevalent malignancy associated with a poor patient prognosis. We investigated the relationship between microRNA‑223 (miR‑223) expression and the sensitivity of HCC cells to sorafenib treatment. miR‑223 expression was determined in HCC cell lines with differential sorafenib sensitivity using reverse transcription‑quantitative PCR. miR‑...
Source: Oncology Reports - December 13, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Authors: Wang J, Xia C, Pu M, Dai B, Yang X, Shang R, Yang Z, Zhang R, Tao K, Dou K Abstract Cell division cycle associated 5 (CDCA5) has been associated with the progression of several types of cancers. However, its possible role and mechanism in hepatocellular carcinoma (HCC) remain unknown. In the present study, immunohistochemical staining and real‑time PCR were used to assess CDCA5 protein and mRNA levels in clinical samples. Statistical analysis was performed to explore the clinical correlation between CDCA5 protein expression and clinicopathological features and overall survival in HCC patients. Cell coun...
Source: Oncology Reports - July 18, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
This study is aimed to investigate the association between EPHA3 expression and androgen receptor (AR) signaling and the potential mechanism. We determined mRNA and protein levels of EPHA3 and AR signaling‑related genes in the PCa cell line 22Rv1 by reverse transcription‑polymerase chain reaction (RT‑PCR) and western blotting, respectively. The EPHA3 mRNA and protein levels were both found to be elevated by dihydrotestosterone (DHT) hormone in a dose‑ and time‑dependent manner, as AR and prostate‑specific antigen (PSA) expression were increased. Similarly, EPHA3 protein levels were also increased in the PCa cel...
Source: Oncology Reports - June 22, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

HBsAg/ β2GPI activates the NF‑κB pathway via the TLR4/MyD88/IκBα axis in hepatocellular carcinoma.
HBsAg/β2GPI activates the NF‑κB pathway via the TLR4/MyD88/IκBα axis in hepatocellular carcinoma. Oncol Rep. 2018 Jun 19;: Authors: Jing X, Tian Z, Gao P, Xiao H, Qi X, Yu Y, Ding X, Yang L, Zong L Abstract Chronic hepatitis B virus (HBV) infection remains one of the leading causes of hepatocellular carcinoma (HCC) globally. However, the mechanism underlying the mediation by HBV surface proteins (HBsAgs) of the early steps in the virus life cycle and following HCC development is unclear. β‑2‑glycoprotein I (β2GPI) specifically interacts with HBsAg and demonstrates high expression during t...
Source: Oncology Reports - June 22, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

ClC-3 chloride channel protein induces G1  arrest in hepatocellular carcinoma Hep3B cells.
In conclusion, we demonstrated that ClC-3 can arrest the cell cycle at the G1 phase to inhibit cell proliferation, suggesting that ClC-3 has the potential to be a novel target for HCC therapy and potentially improve the prognosis of HCC patients. PMID: 29749557 [PubMed - as supplied by publisher]
Source: Oncology Reports - May 12, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
Authors: Jeon JY, Lee JS, Park ER, Shen YN, Kim MY, Shin HJ, Joo HY, Cho EH, Moon SM, Shin US, Park SH, Han CJ, Choi DW, Gu MB, Kim SB, Lee KH Abstract Protein arginine methyltransferase 5 (PRMT5) is a protein that catalyzes transfer of methyl groups to the arginine residues of proteins and is involved in diverse cellular and biological responses. While the participation of PRMT5 in cancer progression has been increasingly documented, its association with the invasive phenotype currently remains poorly understood. In the present study, we revealed that PRMT5 is overexpressed in human hepatocellular carcinoma (HCC...
Source: Oncology Reports - May 12, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Pages: 1  2  3  4